|
[1]Tox U, Steffen HM.Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension[J].Gurr Med Chem, 2006, 13 (30) ∶3649-61.
|
|
[2]Helmy A, Jalan R, Newby DE, et al.Role of angiotensinⅡin reg-ulation of basal and sympathetically stimulated vascular tone in earlyand advanced cirrhosis[J].Gastroenterology, 2000, 118 (3) ∶565-72.
|
|
[3]Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al.Inflammation and an-giotensinⅡ[J].Int J Biochem Cell Biol, 2003, 35 (6) ∶881-900.
|
|
[4]Yang L, Bataller R, Dulyx J, et al.Attenuated hepatic inflammationand fibrosis in angiotensin type 1a receptor deficient mice[J].J Hep-atol, 2005, 43 (2) ∶317-23.
|
|
[5]Ruiz-Ortega M, Lorenzo O, Ruperez M, et al.Renin-angiotensinsystem and renal damage:emerging data on angiotensinⅡas aproinflammatory mediator[J].Contrib Nephrol, 2001 (135) ∶123-37.
|
|
[6]Weinstock JV.The significance of angiotensinⅠconverting enzymein granulomatous inflammation.Functions of ACE in granulomas[J].Sarcoidosis, 1986, 3 (1) ∶19-26.
|
|
[7]Yamada T, Kuno A, Masuda K, et al.Candesartan, an angiotensinⅡreceptor antagonist, suppresses pancreatic inflammation and fibro-sis in rats[J].J Pharmacol Exp Ther, 2003, 307 (1) ∶17-23.
|
|
[8]Yoshiji H, Yoshii J, Ikenaka Y, et al.Inhibition of renin-angio-tensin system attenuates liver enzyme-altered preneoplastic lesionsand fibrosis development in rats[J].J Hepatol, 2002, 37 (1) ∶22-30.
|
|
[9]Olaso E, Friedman SL.Molecular regulation of hepaticfibrogenesis[J].J Hepatol, 1998, 29 (5) ∶836-47.
|
|
[10]Li D, Friedman SL.Liver fibrogenesis and the role of hepatic stel-late cells:new insights and prospects for therapy[J].J GastroenterolHepatol, 1999, 14 (7) ∶618-33.
|
|
[11]Bataller R, Gines P, Nicolas JM, et al.AngiotensinⅡinducescontraction and proliferation of human hepatic stellate cells[J].Gas-troenterology, 2000, 118 (6) ∶1149-56.
|
|
[12]Bataller R, Sancho-Bru P, Gines P, et al.Activated human he-patic stellate cells express the renin-angiotensin system and synthe-size angiotensinⅡ[J].Gastroenterology, 2003, 125 (1) ∶117-25.
|
|
[13]Baik SK, Jo HS, Suk KT, et al.Inhibitory effect of angiotensinⅡreceptor antagonist on the contraction and growth of hepatic stellatecells[J].Korean J Gastroenterol, 2003, 42 (2) ∶134-41.
|
|
[14]Kurikawa N, Suga M, Kuroda S, et al.An angiotensinⅡtype 1receptor antagonist, olmesartan medoxomil, improves experimentalliver fibrosis by suppression of proliferation and collagen synthesis inactivated hepatic stellate cells[J].Br J Pharmacol, 2003, 139 (6) ∶1085-94.
|
|
[15]Li X, Meng Y, Cai SX, et al.AngiotensinⅡand aldosterone stim-ulate alphal- (Ⅰ) procollagen mRNA expression in hepatic stellatecells via activation of ERK1/2 and AP-1[J].Zhonghua Yi Xue ZaZhi, 2005, 85 (26) ∶1831-5.
|
|
[16]Bataller R, Schwabe RF, Choi YH, et al.NADPH oxidase signaltransduces angiotensinⅡin hepatic stellate cells and is critical inhepatic fibrosis[J].J Clin Invest, 2003, 112 (9) ∶1383-94.
|
|
[17]Friedman SL.The answer:angiotensinⅡ.The question:what doinflammation, oxidant stress and fibrogenesis have in common?[J].J Hepatol, 2004, 40 (6) ∶1050-2.
|
|
[18]Eagleton MJ, Ballard N, Lynch E, et al.Early increased MT1-MMP expression and late MMP-2 and MMP-9 activity during An-giotensinⅡinduced aneurysm formation[J].J Surg Res, 2006, 135 (2) ∶345-51.
|
|
[19]Jonsson JR, Clouston Ad, Ando Y, et al.Angiotensin-convertingenzyme inhibition attenuates the progression of rat hepaticfibrosis[J].Gastroenterology, 2001, 121 (1) ∶148-55.
|
|
[20]Castoldi G, Di Gioia CR, Pieruzzi F, et al.ANGⅡincreasesTIMP-1 expression in rat aortic smooth muscle cells in vivo[J].AmJ Physiol Heart Circ Physiol, 2003, 284 (2) ∶H635-43.
|
|
[21]Friedman SL, Rockey DC, Bissell DM.Hepatic fibrosis 2006:re-port of the Third AASLD Single Topic Conference[J].Hepatology, 2007, 45 (1) ∶242-9.
|
|
[22]Laragh JH, Cannon PJ, Ames RP.interaction between aldosteronesecretion.sodium and potassium balance, and angiotensin activity inman:studies in hypertension and cirrhosis[J].Can Med Assoc J, 1964, 90∶248-56.
|
|
[23]Wilkinson SP, Williams R.Renin-angiotensin-aldosterone sys-tem in cirrhosis[J].Gut, 1980, 21 (6) ∶545-54.
|
|
[24]Schneider AW, Kalk JF, Klein CP.Effect of losartan, an angioten-sinⅡreceptor antagonist, on portal pressure in cirrhosis[J].Hepa-tology, 1999, 29 (2) ∶334-9.
|
|
[25]Gonzalez-Abraldes J, Albillos A, Banares R, et al.Randomizedcomparison of long-term losartan versus propranolol in lowering por-tal pressure in cirrhosis[J].Gastroenterology, 2001, 121 (2) ∶382-8.
|
|
[26]Tripathi D, Therapondos G, Lui HF, et al.Chronic administrationof losartan, an angiotensinⅡreceptor antagonist, is not effective inreducing portal pressure in patients with preascitic cirrhosis[J].AmJGastroenterol, 2004, 99 (2) ∶390-4.
|
|
[27]Schepke M, Werner E, Biecker E, et al.Hemodynamic effects ofthe angiotensinⅡreceptor antagonist irbesartan in patients with cir-rhosis and portal hypertension[J].Gastroenterology, 2001, 121 (2) ∶389-95.
|
|
[28]Girgrah N, Liu P, Collier J, et al.Haemodynamic, renal sodiumhandling, and neurohormonal effects of acute administration of lowdose losartan, an angiotensinⅡreceptor antagonist, in preasciticcirrhosis[J].Gut, 2000, 46 (1) ∶114-20.
|
|
[29]Powell EE, Edwards-Smith CJ, Hay JL, et al.Host genetic fac-tors influence disease progression in chronic hepatitis C[J].Hepatol-ogy, 2000, 31 (4) ∶828-33.
|
|
[30]Forrest EH, Thorburn D, Spence E, et al.Polymorphisms of therenin-angiotensin system and the severity of fibrosis in chronic hep-atitis C virus infection[J].J Viral Hepat, 2005, 12 (5) ∶519-24.
|
|
[31]Rimola A, Londono MC, Guevara G, et al.Beneficial effect of an-giotensin-blocking agents on graft fibrosis in hepatitis C recurrenceafter liver transplantation[J].Transplantation, 2004, 78 (5) ∶686-91.
|
|
[32]Sookoian S, Fernandez MA, Castano G.Effects of six months losar-tan administration on liver fibrosis in chronic hepatitis C patients:apilot study[J].World J Gastroenterol, 2005, 11 (48) ∶7560-3.
|
|
[33]Yoshiji H, Noguchi R, Kojima H, et al.Interferon augments theanti-fibrotic activity of an angiotensin-converting enzyme inhibitorin patients with refractory chronic hepatitis C[J].World J Gastroen-terol, 2006, 12 (42) ∶6786-91.
|
|
[34]Yoshiji H, Kuriyama S, Noguchi R, et al.Combination of interfer-on-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development[J].Liver Int, 2005, 25 (1) ∶153-61.
|
PDF下载 ( 221 KB)
本文二维码
下载:
